# Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation

> **NCT02181361** · — · COMPLETED · sponsor: **Xijing Hospital** · enrollment: 239 (actual)

## Conditions studied

- Cardioembolic Stroke
- Atrial Fibrillation

## Interventions

- **DRUG:** hirudin plus aspirin
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT02181361
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-12
- **Final completion:** 2018-10
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2020-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181361, "Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02181361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*